-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! Shijiazhuang Sihua Pharmaceutical Group’s Tinidazole API Has Been Approved
Category:
发布时间：2023-02-06
【概要描述】
During the Beginning of Spring, good news has been coming one after another. On February 6, tinidazole, submitted by Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms.
During the Beginning of Spring, good news has been coming one after another. On February 6, tinidazole, submitted by Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms.
This also marks another significant achievement in the Group’s API development, following the simultaneous approval on February 2 of its Class III new chemical drugs—ornidazole injection (3 mL: 0.5 g and 6 mL: 1 g) and alpha-lipoic acid injection (24 mL: 600 mg). To date this year, the Group has secured approval for a total of nine new products.
According to reports, tinidazole is primarily indicated for sepsis and respiratory tract infections caused by anaerobic bacteria.
The approval of this metronidazole API will play a positive role in advancing the Group’s “API-plus-formulation” development strategy and accelerating the deep integration of the innovation chain with the industrial chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091